Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

The restaurant group announced Tuesday that Jose Alberto Dueñas is stepping down. Chief financial officer Paul Carbone, a ...

Bloks Group Ltd., the popular maker of Ultraman and Transformers figurines, raised HK$1.67 billion ($215 million) in Hong ...

(Reuters) -Oilfield services provider Flowco Holdings on Tuesday said it is seeking a valuation of up to $2 billion in its ...

Spanish travel technology firm HBX Group is considering announcing plans for an initial public offering as early as next week ...

The initial public offering (IPO) of Standard Glass Lining Technology Ltd enters its third and the last day of bidding today, ...

The strong subscription aligns with grey market trends, as Standard Glass Lining's unlisted shares were commanding a premium ...

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...

Leo Dry Fruits shares listed at Rs 68 apiece on the BSE SME, reflecting a premium of Rs 16 or 30.77 per cent over the IPO ...

Laxmi Dental Limited sets its IPO price band between ₹407 and ₹428 per share. Subscription opens on January 13 and closes on ...

Drug developer Maze Therapeutics Inc.'s rollercoaster ride is leading to the Bay Area's first biotech IPO filing of 2025.

The main difference between going public through an initial public offering (IPO) and staying private lies in ownership ...